Ocular Therapeutix Inc (NASDAQ: OCUL)’s stock price has gone rise by 0.28 in comparison to its previous close of 10.86, however, the company has experienced a -1.80% decrease in its stock price over the last five trading days. globenewswire.com reported 2024-10-15 that SOL-1 is now expected to be enrolled and fully randomized by year-end 2024 Topline clinical data from SOL-1 are now expected in Q4 2025 BEDFORD, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) — Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced accelerated timelines for the SOL-1 Phase 3 registrational clinical trial of AXPAXLI in wet age-related macular degeneration (wet AMD).
Is It Worth Investing in Ocular Therapeutix Inc (NASDAQ: OCUL) Right Now?
Company’s 36-month beta value is 1.27.Analysts have differing opinions on the stock, with 4 analysts rating it as a “buy,” 1 as “overweight,” 2 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for OCUL is 134.99M, and currently, short sellers hold a 12.00% ratio of that floaft. The average trading volume of OCUL on October 25, 2024 was 1.16M shares.
OCUL’s Market Performance
OCUL stock saw an increase of -1.80% in the past week, with a monthly gain of 23.19% and a quarterly increase of 29.18%. The volatility ratio for the week is 4.04%, and the volatility levels for the last 30 days are 5.78% for Ocular Therapeutix Inc (OCUL). The simple moving average for the last 20 days is 8.40% for OCUL’s stock, with a simple moving average of 44.70% for the last 200 days.
Analysts’ Opinion of OCUL
TD Cowen, on the other hand, stated in their research note that they expect to see OCUL reach a price target of $11, previously predicting the price at $7. The rating they have provided for OCUL stocks is “Buy” according to the report published on June 20th, 2024.
Piper Sandler gave a rating of “Overweight” to OCUL, setting the target price at $15 in the report published on May 31st of the current year.
OCUL Trading at 17.71% from the 50-Day Moving Average
After a stumble in the market that brought OCUL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -6.12% of loss for the given period.
Volatility was left at 5.78%, however, over the last 30 days, the volatility rate increased by 4.04%, as shares surge +24.03% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +36.30% upper at present.
During the last 5 trading sessions, OCUL fell by -1.80%, which changed the moving average for the period of 200-days by +130.72% in comparison to the 20-day moving average, which settled at $10.05. In addition, Ocular Therapeutix Inc saw 144.17% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at OCUL starting from PHILIP C. STRASSBURGER, who proposed sale 13,125 shares at the price of $10.23 back on Oct 16 ’24. After this action, PHILIP C. STRASSBURGER now owns shares of Ocular Therapeutix Inc, valued at $134,269 using the latest closing price.
Nayak Sanjay, the Chief Strategy Officer of Ocular Therapeutix Inc, sale 1,832 shares at $9.02 during a trade that took place back on Aug 23 ’24, which means that Nayak Sanjay is holding 176,194 shares at $16,525 based on the most recent closing price.
Stock Fundamentals for OCUL
Current profitability levels for the company are sitting at:
- -1.88 for the present operating margin
- 0.91 for the gross margin
The net margin for Ocular Therapeutix Inc stands at -2.27. The total capital return value is set at -0.23. Equity return is now at value -72.67, with -43.26 for asset returns.
Based on Ocular Therapeutix Inc (OCUL), the company’s capital structure generated 0.15 points at debt to capital in total, while cash flow to debt ratio is standing at -1.22. The debt to equity ratio resting at 0.18. The interest coverage ratio of the stock is 894.29.
Currently, EBITDA for the company is -79.4 million with net debt to EBITDA at 3.42. When we switch over and look at the enterprise to sales, we see a ratio of 21.56. The receivables turnover for the company is 2.01for trailing twelve months and the total asset turnover is 0.12. The liquidity ratio also appears to be rather interesting for investors as it stands at 16.64.
Conclusion
In a nutshell, Ocular Therapeutix Inc (OCUL) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
